Evolocumab Safe and Effective in Pediatric FH Evolocumab Safe and Effective in Pediatric FH

The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pediatric population.Medscape Medical News
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Cardiology News Source Type: news